Cognitive Function News and Research

RSS

Cognition is a concept used in different ways by different disciplines, but is generally accepted to mean the process of thought. For example, in psychology and cognitive science it refers to an information processing view of an individual's psychological functions.

Three hundred participants sought for world-first study to determine shared biological basis for psychotic illnesses

For the first time, sufferers of schizophrenia and bipolar disorder are being brought together in a major new study investigating the diseases' common genetic causes and manifestations.

11 Oct 2009

University of Florida to study whether exercise can prevent disability in older people

The University of Florida will receive $29.5 million in federal stimulus funds over the next two years from the National Institute on Aging to begin a six-year study on whether a program of structured physical activity can prevent or delay major movement disability in older adults.

3 Oct 2009

Orexigen's Empatic Phase 2b results demonstrate weight loss

Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.

1 Oct 2009

Rush University receives grants to study how epigenomic changes define cognitive decline

The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.

1 Oct 2009

New Pathways to Memory Program to improve cognitive function for patients with dementia

Based on the ground-breaking program released in 2005, Homewatch CareGivers (www.HomewatchCareGivers.com), the largest, most experienced international provider of full-service home care, announced the release of its newly expanded Pathways to Memory™ Program, a set of therapeutic activities delivered in a nurturing, failure-free environment that stimulates and enhances cognitive function for patients with early to mid stage dementia, Alzheimer’s disease, and other memory loss conditions.

1 Oct 2009

Overweight middle-age women could reduce their chances of enjoying a healthy old age: Study

Women who put on weight as they approach middle-age could reduce their chances of enjoying a healthy old age by up to 80%, according to research from the University of Warwick.

30 Sep 2009

Study on how epigenetic changes contribute to congnitive decline

28 Sep 2009

Early detection of Alzheimer's can prevent disease progression

More than 5.3 million Americans are living with Alzheimer's, and every 71 seconds someone in America develops the disease.

18 Sep 2009

USPTO grants a provisional patent to INVENT Pharmaceuticals' Alzheimer’s drug

American Diversified Holdings Corporation (Pink Sheets: ADHC) Strategic Alliance partner INVENT Pharmaceuticals, Inc. announced today that the U.S. Patent and Trademark Office has granted its provisional patent application US 61/271,720 on novel drug candidates for the treatment of Alzheimer’s disease and age-related cognitive and memory impairment.

16 Sep 2009

Mild cognitive impairment is a risk factor for dementia

Among individuals with mild cognitive impairment, often considered a transitional state between normal cognitive function and Alzheimer's dementia, those who have more difficulties performing routine activities appear more likely to progress quickly to dementia, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Sep 2009

U.S. Department of Justice awards grant to Project Lifesaver International

Project Lifesaver International, a non-profit organization that helps rescue citizens who are prone to wander due to Alzheimer's disease, autism, and other cognitive disorders, received notification of federal assistance yesterday.

14 Sep 2009

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced data presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) showing the potential of TYSABRI® (natalizumab) to redefine successful multiple sclerosis (MS) therapy.

14 Sep 2009

AAN's ability to mimic the human brain helps diagnose cardiac infections

Mayo Clinic researchers say that "teachable software" designed to mimic the human brain may help them diagnose cardiac infections without an invasive exam. Those findings are being presented today at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

14 Sep 2009

UBC acquires Cognitive Drug Research

United BioSource Corporation (UBC) today announced the acquisition of Cognitive Drug Research, Ltd. (CDR), the leader in computerized cognitive testing for clinical trials.

11 Sep 2009

Higher rate of motor vehicle crashes in MHE patients

A recent study by Jasmohan Bajaj, M.D., and colleagues from Virginia Commonwealth University and McGuire VA Medical Center found that patients with cirrhosis of the liver who developed minimal hepatic encephalopathy (MHE) had a 16% rate of motor vehicle crashes compared to only 4% of those without MHE over one year.

10 Sep 2009

VIVUS' Phase 3 studies find Qnexa effective in tackling obesity

VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.

9 Sep 2009

Clinical criteria for mild cognitive impairment proves better for identifying Alzheimer's disease

A new Mayo Clinic study found that the clinical criteria for mild cognitive impairment is better at predicting who will develop Alzheimer's disease than a single memory test. This is one more piece of information to aid in the identification and early treatment of individuals most likely to develop Alzheimer's disease. This study will be presented at the Alzheimer's Association International Conference on Alzheimer's Disease on July 14 in Vienna.

2 Sep 2009

Chlorella green food sourced from algae contains a wide range of essential nutrients

"While we can still take advantage of summer's fresh produce, ensuring a consistent supply of whole foods throughout the year can reap benefits for those focused on aging as healthfully as possible," says Michael E. Rosenbaum, M.D. "Chlorella, a super green food sourced from a fresh water algae, contains the widest range of essential nutrients available in any single food source, including potassium, all B vitamins, magnesium, zinc, iron and 18 vital amino acids." Though beneficial for all life stages, Sun Chlorella can especially help aging adults thanks to these health rewards.

1 Sep 2009

Biovail enters into an agreement with Santhera to develop and market JP-1730/fipamezole drug

Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera’s JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson’s Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.

24 Aug 2009

RBC Life Sciences reports on patent-pending, nutritional supplement

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements and wound care/pain management products, announced today the debut of NeuroBright(TM), a patent-pending, nutritional supplement that improved test subjects' learning and memory skills by 50 percent during a recent laboratory trial.

20 Aug 2009

Cognitive Function News and Research

Further Reading

Three hundred participants sought for world-first study to determine shared biological basis for psychotic illnesses

University of Florida to study whether exercise can prevent disability in older people

Orexigen's Empatic Phase 2b results demonstrate weight loss

Rush University receives grants to study how epigenomic changes define cognitive decline

New Pathways to Memory Program to improve cognitive function for patients with dementia

Overweight middle-age women could reduce their chances of enjoying a healthy old age: Study

Study on how epigenetic changes contribute to congnitive decline

Early detection of Alzheimer's can prevent disease progression

USPTO grants a provisional patent to INVENT Pharmaceuticals' Alzheimer’s drug

Mild cognitive impairment is a risk factor for dementia

U.S. Department of Justice awards grant to Project Lifesaver International

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

AAN's ability to mimic the human brain helps diagnose cardiac infections

UBC acquires Cognitive Drug Research

Higher rate of motor vehicle crashes in MHE patients

VIVUS' Phase 3 studies find Qnexa effective in tackling obesity

Clinical criteria for mild cognitive impairment proves better for identifying Alzheimer's disease

Chlorella green food sourced from algae contains a wide range of essential nutrients

Biovail enters into an agreement with Santhera to develop and market JP-1730/fipamezole drug

RBC Life Sciences reports on patent-pending, nutritional supplement

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News